Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation
S. Forrest Dodson, Michael E. de Vera, C. Andrew Bonham, David A. Geller, Jorge Rakela, John J. Fung – 30 December 2003 – The prevention of recurrent hepatitis B virus (HBV) infection after orthotopic liver transplantation (OLT) with hepatitis B immunoglobulin (HBIG) is expensive and requires indefinite parenteral administration. Lamivudine is a nucleoside analogue capable of inhibiting HBV replication.